Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that N-methyl-D-aspartate receptor antagonist, memantine, will garner healthy Alzheimer's disease drug market share by 2011. Memantine's market share will be driven by the fact that it will be the first agent approved for the underserved moderate to severe Alzheimer's disease patient population in the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan), according to a new Pharmacor report from Decision Resources entitled Alzheimer's Disease. The novel drug will be used by physicians primarily as a 'tack-on' drug with acetylcholinesterase inhibitors.
"Developers had initially hoped that memantine would prove neuroprotective, but such benefits are unlikely to be significant. Regardless, this drug will garner healthy sales by 2011," said Michelle Grady, analyst at Decision Resources. "Memantine's effect on Alzheimer's disease symptoms is generally unimpressive; nonetheless, most physicians will at least try the drug, probably in combination with an acetylcholinesterase inhibitor, since it may be the only option for patients with more-severe Alzheimer's disease and memantine appears to be well tolerated."
Disease Background-Alzheimer's Disease
Alzheimer's disease is a progressive neurodegenerative disease characterized by significant loss of function in more than one cognitive domain (memory impairment, language disturbance, visual-spatial disturbances, and difficulties with organization, reasoning, or judgment) and often accompanied by changes in behavior or personality. In 2001, in the world's seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan), more than 5 million people had Alzheimer's disease, and drugs to treat the disease generated $936 million in sales.
About Pharmacor from Decision Resources
Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Alzheimer's Disease is a Cognos report.
About Decision Resources
Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at www.decisionresources.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 email@example.com
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
Web site: http://www.dresources.com/